Urgently needed: a filter for the HIV-1 vaccine pipeline
- 1 August 2004
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (8) , 769-771
- https://doi.org/10.1038/nm0804-769
Abstract
Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.Keywords
This publication has 18 references indexed in Scilit:
- HIV vaccine design and the neutralizing antibody problemNature Immunology, 2004
- HIV vaccines 1983–2003Nature Medicine, 2003
- Immunopathogenesis and immunotherapy in AIDS virus infectionsNature Medicine, 2003
- Enhanced: The Need for a Global HIV Vaccine EnterpriseScience, 2003
- Rapid evolution of the neutralizing antibody response to HIV type 1 infectionProceedings of the National Academy of Sciences, 2003
- Occupancy and mechanism in antibody-mediated neutralization of animal virusesJournal of General Virology, 2002
- Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T CellsJournal of Virology, 2002
- Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine DevelopmentJournal of Virology, 2001
- A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1Virology, 2001
- Primary Isolate Neutralization by HIV Type 1-Infected Patient Sera in the Era of Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 1999